MYUNGMOON Pharm co.,Ltd
MYUNGMOON Pharm co.,Ltd (KRX: 017180) is trading at ₩1,286.00, about ₹93 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET, down 2.21% today. MYUNGMOON Pharm is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
₩1,280.00
Today's high
₩1,315.00
52 week low
₩1,000.00
52 week high
₩2,055.00
017180 opened at ₩1,293.00, closed previously at ₩1,315.00, and has traded between ₩1,000.00 and ₩2,055.00 over the past 52 weeks.
About
MYUNGMOON Pharm Co., Ltd. operates as a pharmaceutical enterprise, comprehensively handling the research, development, production, distribution, and commercialization of medicinal products. Its business activities extend across South Korea and into global markets. The company offers an extensive array of prescription drugs, addressing a broad spectrum of medical conditions. This range includes treatments for musculoskeletal issues like osteoarthritis, inflammation, rheumatoid arthritis, and muscle relaxation, alongside anti-infectives (antibiotics and antifungals), respiratory aids, and gastrointestinal therapeutics. Cardiovascular health is targeted with circulation agents, anti-hypertensive drugs, and antidiabetic medications. Furthermore, their specialized pharmacotherapy solutions cover narcotics, anesthetics, central nervous system agents, female hormone products, osteoporosis treatments, urogenital medications, adrenocortical hormones, oncology drugs, dermal fillers, and anti-obesity agents. Beyond prescription items, MYUNGMOON Pharm also supplies a diverse selection of over-the-counter (OTC) remedies. These encompass medications for nausea, genitourinary concerns, gum disease, liver support, parasitic infections, constipation, oral ailments, diarrhea, and general digestive health. The OTC portfolio further includes cold and flu treatments, calcium supplements, nasal sprays, multi-vitamins, eye nutrition products, eye drops, blood circulation enhancers, and topical preparations such as external skin treatments and localized pain relievers. In addition to its pharmaceutical lines, the firm markets health supplements, quasi-pharmaceuticals, and blended juice beverages. Established in 1983, MYUNGMOON Pharm Co., Ltd. maintains its primary corporate office in Seoul, South Korea.
Key statistics
Avg. volume
388.00K
Market cap
₩42.99B
P/E Ratio
-21.31
Price-to-sales ratio
0.22
Enterprise value
₩155.61B
Free cash flow yield
-13.47%
Debt-to-equity ratio
0.89
Return on equity
1.92%
ROIC
1.58%
Beta
0.28
Dividend yield
0.00%
Last dividend
₩0.00
Financial overview
Revenue
₩195.25B
Earnings per share
₩56.70
Free cash flow
-₩8.46B
Net profit margin
-0.83%
Gross margin
57.27%
EBITDA
₩10.13B
Revenue growth
4.72%
Similar securities
This is not an investment recommendation
MYUNGMOON Pharm for Indian investors
MYUNGMOON Pharm is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on MYUNGMOON Pharm for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm KST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneMYUNGMOON Pharm does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
FAQs
Can I buy MYUNGMOON Pharm on Paasa?
MYUNGMOON Pharm (017180) has been listed on the Korea Exchange since 2008, in the Drug Manufacturers - Specialty & Generic industry. MYUNGMOON Pharm is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one MYUNGMOON Pharm share cost in rupees?
One MYUNGMOON Pharm share is ₩1,286.00 — about ₹93 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the MYUNGMOON Pharm price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on MYUNGMOON Pharm shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the MYUNGMOON Pharm price.
Does MYUNGMOON Pharm pay a dividend?
No. MYUNGMOON Pharm does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one: dividends are taxed at your slab rate in India.
When does KRX trade, in Indian time?
The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.
Do I have to declare MYUNGMOON Pharm shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on MYUNGMOON Pharm?
Yes. MYUNGMOON Pharm is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.